Independent commentary on selected presentations has been made by Dr Henry Chan from Auckland, and Associate Professor Hang Quach from Melbourne, who attended the meeting.
Highlights include:
- KRd ± SCT or KCd regimen for new multiple myeloma.
- Double or single autologous SCT for new multiple myeloma.
- Selinexor + dexamethasone in pentarefractory multiple myeloma.
- Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Please login below to download this issue (PDF)